Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Risperidone | 19 | 2018 | 62 | 7.940 |
Why?
|
| Depressive Disorder, Major | 16 | 2021 | 436 | 5.770 |
Why?
|
| Antipsychotic Agents | 23 | 2024 | 429 | 4.880 |
Why?
|
| Bone Density | 8 | 2023 | 466 | 2.770 |
Why?
|
| Weight Gain | 10 | 2023 | 471 | 2.710 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2023 | 240 | 1.910 |
Why?
|
| Anxiety Disorders | 5 | 2019 | 725 | 1.700 |
Why?
|
| Bone and Bones | 4 | 2017 | 605 | 1.620 |
Why?
|
| Depression | 6 | 2024 | 1730 | 1.610 |
Why?
|
| Anxiety | 4 | 2024 | 1240 | 1.400 |
Why?
|
| Ferritins | 5 | 2024 | 156 | 1.400 |
Why?
|
| Autism Spectrum Disorder | 3 | 2023 | 377 | 1.350 |
Why?
|
| Adolescent | 47 | 2024 | 32767 | 1.330 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 2 | 2018 | 59 | 1.200 |
Why?
|
| Sexual Behavior | 2 | 2021 | 313 | 1.100 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 138 | 1.100 |
Why?
|
| Hyperprolactinemia | 3 | 2017 | 20 | 1.020 |
Why?
|
| Absorptiometry, Photon | 8 | 2017 | 235 | 0.960 |
Why?
|
| Iron | 4 | 2024 | 380 | 0.920 |
Why?
|
| Child | 35 | 2024 | 30559 | 0.920 |
Why?
|
| Metabolic Syndrome | 3 | 2014 | 369 | 0.920 |
Why?
|
| Sertraline | 1 | 2023 | 42 | 0.880 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 317 | 0.840 |
Why?
|
| Autonomic Nervous System | 2 | 2023 | 72 | 0.830 |
Why?
|
| Metformin | 2 | 2023 | 393 | 0.820 |
Why?
|
| Mental Disorders | 5 | 2019 | 882 | 0.780 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 69 | 0.740 |
Why?
|
| Hyperglycemia | 1 | 2023 | 337 | 0.710 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 335 | 0.710 |
Why?
|
| Movement Disorders | 1 | 2023 | 234 | 0.710 |
Why?
|
| Migraine Disorders | 2 | 2020 | 84 | 0.700 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 980 | 0.670 |
Why?
|
| Catatonia | 1 | 2019 | 13 | 0.660 |
Why?
|
| Male | 47 | 2024 | 128315 | 0.660 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 54 | 0.640 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2015 | 43 | 0.630 |
Why?
|
| Steroids | 2 | 2019 | 372 | 0.620 |
Why?
|
| Sexual Maturation | 1 | 2018 | 55 | 0.620 |
Why?
|
| Cyclosporine | 1 | 2019 | 292 | 0.610 |
Why?
|
| Calcium Carbonate | 1 | 2017 | 28 | 0.600 |
Why?
|
| Cholecalciferol | 1 | 2017 | 48 | 0.590 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 20 | 0.580 |
Why?
|
| Body Mass Index | 11 | 2023 | 2232 | 0.570 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 95 | 0.570 |
Why?
|
| Young Adult | 15 | 2023 | 22251 | 0.550 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 83 | 0.540 |
Why?
|
| Toxoplasma | 1 | 2016 | 14 | 0.540 |
Why?
|
| Humans | 60 | 2024 | 270740 | 0.540 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2023 | 772 | 0.540 |
Why?
|
| Basal Ganglia Diseases | 1 | 2016 | 32 | 0.530 |
Why?
|
| Lumbar Vertebrae | 4 | 2023 | 247 | 0.520 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 30 | 0.520 |
Why?
|
| Bacteroidetes | 1 | 2015 | 23 | 0.520 |
Why?
|
| Firmicutes | 1 | 2015 | 22 | 0.520 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 49 | 0.520 |
Why?
|
| Central Nervous System Stimulants | 3 | 2013 | 193 | 0.510 |
Why?
|
| Problem Behavior | 1 | 2016 | 38 | 0.510 |
Why?
|
| Female | 39 | 2024 | 148940 | 0.510 |
Why?
|
| Serotonin Antagonists | 1 | 2015 | 50 | 0.500 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 130 | 0.480 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 1024 | 0.470 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 147 | 0.460 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 4492 | 0.460 |
Why?
|
| Body Composition | 1 | 2017 | 606 | 0.460 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 140 | 0.450 |
Why?
|
| Adiposity | 1 | 2015 | 238 | 0.450 |
Why?
|
| Electroconvulsive Therapy | 2 | 2004 | 63 | 0.440 |
Why?
|
| Comorbidity | 5 | 2023 | 2394 | 0.440 |
Why?
|
| Antifungal Agents | 1 | 2019 | 880 | 0.420 |
Why?
|
| Prolactin | 4 | 2016 | 169 | 0.420 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 1557 | 0.420 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 464 | 0.410 |
Why?
|
| Gene Deletion | 1 | 2017 | 1474 | 0.410 |
Why?
|
| Overweight | 1 | 2016 | 484 | 0.400 |
Why?
|
| Bipolar Disorder | 1 | 2015 | 358 | 0.400 |
Why?
|
| Obesity | 4 | 2023 | 2904 | 0.400 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 53 | 0.390 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 8 | 0.370 |
Why?
|
| Pilot Projects | 5 | 2021 | 2828 | 0.370 |
Why?
|
| Isoxazoles | 1 | 2011 | 81 | 0.360 |
Why?
|
| Methylphenidate | 1 | 2010 | 91 | 0.350 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 15218 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2021 | 905 | 0.340 |
Why?
|
| Cytokines | 1 | 2018 | 2825 | 0.340 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2009 | 67 | 0.320 |
Why?
|
| Glycine | 1 | 2010 | 322 | 0.310 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2021 | 219 | 0.310 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 115 | 0.300 |
Why?
|
| Leptin | 1 | 2009 | 306 | 0.300 |
Why?
|
| Child, Preschool | 7 | 2018 | 17061 | 0.290 |
Why?
|
| Linear Models | 3 | 2017 | 1093 | 0.290 |
Why?
|
| Fluoxetine | 1 | 2005 | 46 | 0.260 |
Why?
|
| Emotions | 3 | 2019 | 560 | 0.250 |
Why?
|
| Imagination | 2 | 2008 | 22 | 0.250 |
Why?
|
| Prospective Studies | 5 | 2019 | 13414 | 0.240 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 2057 | 0.240 |
Why?
|
| Demography | 2 | 2017 | 433 | 0.240 |
Why?
|
| Sex Characteristics | 2 | 2017 | 425 | 0.230 |
Why?
|
| Methohexital | 1 | 2003 | 3 | 0.230 |
Why?
|
| Algorithms | 1 | 2015 | 3891 | 0.230 |
Why?
|
| Methyl Ethers | 1 | 2003 | 29 | 0.230 |
Why?
|
| Mental Processes | 1 | 2003 | 53 | 0.230 |
Why?
|
| Anesthetics, Intravenous | 1 | 2003 | 71 | 0.220 |
Why?
|
| Myasthenia Gravis | 1 | 2004 | 106 | 0.220 |
Why?
|
| Anesthetics, Inhalation | 1 | 2003 | 65 | 0.220 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2023 | 38 | 0.220 |
Why?
|
| Treatment Outcome | 9 | 2023 | 33737 | 0.210 |
Why?
|
| Acceptance and Commitment Therapy | 2 | 2020 | 42 | 0.200 |
Why?
|
| Orgasm | 1 | 2021 | 12 | 0.200 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2021 | 14 | 0.200 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 278 | 0.190 |
Why?
|
| Quinolones | 2 | 2013 | 163 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 416 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 4372 | 0.180 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 2224 | 0.180 |
Why?
|
| Qualitative Research | 1 | 2024 | 642 | 0.180 |
Why?
|
| Sex Factors | 2 | 2019 | 2184 | 0.180 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 237 | 0.170 |
Why?
|
| Avoidance Learning | 1 | 2019 | 95 | 0.160 |
Why?
|
| Respiratory Sinus Arrhythmia | 1 | 2018 | 9 | 0.160 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 79 | 0.160 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 511 | 0.160 |
Why?
|
| Double-Blind Method | 2 | 2017 | 2580 | 0.160 |
Why?
|
| Permeability | 1 | 2018 | 160 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2011 | 3669 | 0.150 |
Why?
|
| Seizures | 1 | 2003 | 1001 | 0.150 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 51 | 0.150 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 2345 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2019 | 610 | 0.150 |
Why?
|
| Prevalence | 2 | 2017 | 3404 | 0.140 |
Why?
|
| Asymptomatic Infections | 1 | 2016 | 38 | 0.130 |
Why?
|
| Iron Metabolism Disorders | 1 | 2015 | 14 | 0.130 |
Why?
|
| Risk Factors | 4 | 2019 | 17888 | 0.130 |
Why?
|
| Aggression | 2 | 2023 | 250 | 0.130 |
Why?
|
| Biomarkers | 2 | 2021 | 5051 | 0.130 |
Why?
|
| Interview, Psychological | 1 | 2016 | 106 | 0.130 |
Why?
|
| Serologic Tests | 1 | 2016 | 147 | 0.130 |
Why?
|
| Social Perception | 2 | 2008 | 74 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 94 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4328 | 0.120 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 136 | 0.120 |
Why?
|
| Adult | 10 | 2023 | 82040 | 0.120 |
Why?
|
| Time Factors | 3 | 2018 | 13006 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2016 | 453 | 0.120 |
Why?
|
| Brain | 2 | 2008 | 4208 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2023 | 1269 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 1199 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2017 | 1571 | 0.120 |
Why?
|
| Inflammation | 2 | 2021 | 2518 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2013 | 5056 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 260 | 0.110 |
Why?
|
| Interleukin-6 | 2 | 2021 | 1050 | 0.110 |
Why?
|
| Piperazines | 2 | 2013 | 2145 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2017 | 562 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2015 | 232 | 0.110 |
Why?
|
| Skinfold Thickness | 1 | 2012 | 34 | 0.100 |
Why?
|
| ROC Curve | 1 | 2016 | 1248 | 0.100 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2014 | 256 | 0.100 |
Why?
|
| Logistic Models | 1 | 2019 | 3444 | 0.100 |
Why?
|
| Conduct Disorder | 1 | 2011 | 32 | 0.100 |
Why?
|
| Paliperidone Palmitate | 1 | 2011 | 4 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2011 | 6 | 0.100 |
Why?
|
| Sexual Development | 1 | 2011 | 23 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1568 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 45 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 62 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2023 | 6224 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 925 | 0.090 |
Why?
|
| Radiography | 1 | 2015 | 1986 | 0.090 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2011 | 87 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 267 | 0.090 |
Why?
|
| Radius | 1 | 2010 | 45 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 7783 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 684 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2013 | 565 | 0.080 |
Why?
|
| Puberty | 1 | 2010 | 97 | 0.080 |
Why?
|
| Calcium | 1 | 2016 | 1578 | 0.080 |
Why?
|
| Growth | 1 | 2010 | 125 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 146 | 0.080 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 1330 | 0.080 |
Why?
|
| Anthropometry | 1 | 2010 | 262 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2009 | 100 | 0.080 |
Why?
|
| Child Behavior Disorders | 1 | 2009 | 74 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 564 | 0.080 |
Why?
|
| Oxygen Radioisotopes | 2 | 2008 | 7 | 0.080 |
Why?
|
| Tic Disorders | 1 | 2009 | 78 | 0.080 |
Why?
|
| Schizophrenic Psychology | 1 | 2008 | 82 | 0.070 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 494 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 362 | 0.070 |
Why?
|
| DNA Primers | 1 | 2009 | 1496 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2650 | 0.070 |
Why?
|
| United States | 1 | 2024 | 15861 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 310 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2008 | 274 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2012 | 732 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2012 | 1568 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2009 | 1246 | 0.070 |
Why?
|
| Schizophrenia | 1 | 2008 | 317 | 0.060 |
Why?
|
| Alleles | 1 | 2011 | 2600 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 17 | 0.060 |
Why?
|
| Testosterone | 1 | 2010 | 638 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2017 | 9470 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2023 | 39890 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2008 | 624 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 311 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 22505 | 0.060 |
Why?
|
| Thinking | 1 | 2003 | 36 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 32 | 0.060 |
Why?
|
| Acceleration | 1 | 2023 | 25 | 0.060 |
Why?
|
| Genotype | 1 | 2011 | 4252 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2011 | 2166 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 3476 | 0.050 |
Why?
|
| Awareness | 1 | 2003 | 115 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 3530 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1534 | 0.050 |
Why?
|
| Base Sequence | 1 | 2009 | 5437 | 0.050 |
Why?
|
| Aripiprazole | 2 | 2013 | 22 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2008 | 762 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 521 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 334 | 0.050 |
Why?
|
| Self Concept | 1 | 2003 | 198 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2003 | 239 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 352 | 0.050 |
Why?
|
| Social Behavior | 1 | 2003 | 310 | 0.050 |
Why?
|
| Water | 1 | 2003 | 386 | 0.050 |
Why?
|
| Resistin | 1 | 2021 | 42 | 0.050 |
Why?
|
| Nerve Net | 1 | 2003 | 272 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 659 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2020 | 58 | 0.040 |
Why?
|
| Machine Learning | 1 | 2023 | 360 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 949 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 97 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 127 | 0.040 |
Why?
|
| Middle Aged | 4 | 2020 | 90352 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 959 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 1584 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 30998 | 0.030 |
Why?
|
| Exercise | 1 | 2023 | 1184 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 5776 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 745 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 13999 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1824 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 231 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2019 | 1043 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2013 | 182 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 263 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 312 | 0.020 |
Why?
|
| Control Groups | 1 | 2008 | 12 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2008 | 58 | 0.020 |
Why?
|
| Reading | 1 | 2008 | 86 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 114 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5923 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 7895 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 514 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 1145 | 0.010 |
Why?
|
| Age Factors | 1 | 2013 | 5457 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 8130 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8699 | 0.010 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2197 | 0.010 |
Why?
|
| Aged | 1 | 2004 | 73333 | 0.010 |
Why?
|